|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer:an open-label,randomized controlled phase 3 trial(ORIENT-3)显示文摘Background:Treatment options for Chinese patients with locally advanced or metastatic squamous-cell non-small-cell lung cancer(sqNSCLC)after failure of first-line chemotherapy are limited.This study(ORIENT-3)aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second-line treatment in patients with locally advanced or metastatic sqNSCLC.Methods:ORIENT-3 was an open-label,multicenter,randomized controlled phase 3 trial that recruited patients with stage IIIB/IIIC/IV sqNSCLC after failure with first-line platinum-based chemotherapy.Patients were randomized in a 1:1 ratio to receive either 200 mg of sintilimab or 75 mg/m^(2) of docetaxel intravenously every 3 weeks,stratified by the Eastern Cooperative Oncology Group performance status.The primary endpoint was overall survival(OS)in the full analysis set(FAS).Secondary endpoints included progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),duration of response(DoR)and safety.Results:Between August 25,2017,and November 7,2018,290 patients were randomized.For FAS,10 patients fromthe docetaxel armwere excluded.Themedian OS was 11.79(n=145;95%confidence interval[CI],10.28-15.57)months with sintilimab versus 8.25(n=135;95%CI,6.47-9.82)months with docetaxel(hazard ratio[HR]:0.74;95%CI,0.56-0.96;P=0.025).Sintilimab treatment significantly prolonged PFS(median 4.30 vs.2.79 months;HR:0.52;95%CI,0.39-0.68;P<0.001)and showed higher ORR(25.50%vs.2.20%,P<0.001)and DCR(65.50%vs.37.80%,P<0.001)than the docetaxel arm.The median DoRwas 12.45(95%CI,4.86-25.33)months in the sintilimab arm and 4.14(95%CI,1.41-7.23)months in the docetaxel arm(P=0.045).Treatment-related adverse events of grade≥3were reported in 26(18.1%)patients in the sintilimab arm and 47(36.2%)patients in the docetaxel arm.Exploratory biomarker analysis showed potential predictive values of expression levels of two transcription factors,including OVOL2(HR:0.35;P<0.001)and CTCF(HR:3.50;P<0.001),for sintilimab treatment.Conclusions:Compared with docetaxel,sintilimab significantly improved the OS,PFS,and ORR of Chinese patients with previously treated locally advanced or metastatic sqNSCLC. | Yuankai Shi Lin Wu Xinmin Yu Puyuan Xing Yan Wang Jianying Zhou Airong Wang Jianhua Shi Yi Hu Ziping Wang Guangyu An Yong Fang Sanyuan Sun Caicun Zhou Changli Wang Feng Ye Xingya Li Junye Wang Mengzhao Wang Yunpeng Liu Yanqiu Zhao Ying Yuan Jifeng Feng Zhendong Chen Jindong Shi Tao Sun Gang Wu Yongqian Shu Qisen Guo Yi Zhang Yong Song Shucai Zhang Yuan Chen Wei Li Hongrui Niu Wenwei Hu Lijun Wang Jianan Huang Yang Zhang Ying Cheng Zhengdong Wu Bo Peng Jiya Sun Christoph Mancao Yanqi Wang Luyao Sun | 2022 | Cancer Communications2022，42，12： | 8 |
| 2 | Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC:a multicenter phase-II trial显示文摘This multicenter phase-II trial aimed to investigate the efficacy,safety,and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC.Patients who failed from first-line EGFR-TKIs and did not harbor T790M mutation were enrolled.Toripalimab plus carboplatin and pemetrexed were administrated every three weeks for up to six cycles,followed by the maintenance of toripalimab and pemetrexed.The primary endpoint was objective-response rate(ORR).Integrated biomarker analysis of PD-L1 expression,tumor mutational burden(TMB),CD8+tumor-infiltrating lymphocyte(TIL)density,whole-exome,and transcriptome sequencing on tumor biopsies were also conducted.Forty patients were enrolled with an overall ORR of 50.0%and disease-control rate(DCR)of 87.5%.The median progression free survival(PFS)and overall survival were 7.0 and 23.5 months,respectively.The most common treatment-related adverse effects were leukopenia,neutropenia,anemia,ALT/AST elevation,and nausea.Biomarker analysis showed that none of PD-L1 expression,TMB level,and CD8+TIL density could serve as a predictive biomarker.Integrated analysis of whole-exome and transcriptome sequencing data revealed that patients with DSPP mutation had a decreased M2 macrophage infiltration and associated with longer PFS than those of wild type.Toripalimab plus chemotherapy showed a promising anti-tumor activity with acceptable safety profiles as the second-line setting in patients with EGFR-mutant NSCLC.DSPP mutation might serve as a potential biomarker for this combination.A phase-III trial to compare toripalimab versus placebo in combination with chemotherapy in this setting is ongoing(NCT03924050). | Tao Jiang Pingyang Wang Jie Zhang Yanqiu Zhao Jianying Zhou Yun Fan Yongqian Shu Xiaoqing Liu Helong Zhang Jianxing He Guanghui Gao Xiaoqian Mu Zhang Bao Yanjun Xu Renhua Guo Hong Wang Lin Deng Ningqiang Ma Yalei Zhang Hui Feng Sheng Yao Jiarui Wu Luonan Chen Caicun Zhou Shengxiang Ren | 2021 | Signal Transduction and Targeted Therapy2021，6，11： | 8 |
| 3 | The improved FASTmrEMMA and GCIM algorithms for genome-wide association and linkage studies in large mapping populations显示文摘Owing to high power and accuracy and low false positive rate in our multi-locus approaches for genome-wide association studies and linkage analyses,these approaches have attracted considerable attention in plant and animal genetics.In large mapping population,however,fast multi-locus random-SNP-effect efficient mixed model association(FASTmrEMMA)and genome-wide composite interval mapping(GCIM)run a relatively long time.To address this issue,we proposed the improved FASTmrEMMA and GCIM algorithms in this study.In the new algorithms,some matrix identities,such as the Woodbury matrix identity,were used.In scanning each marker on the entire genome,in other words,the improved algorithms effectively replace the expensive eigenvector solutions in(restricted)maximum likelihood estimations in original algorithms with two(one)updated inner products and one updated vector-matrix-vector multiplication.Simulated and real data analyses showed that their computational efficiencies are increased sharply in large mapping population,although there are no mapping result differences between original and improved algorithms.In addition,the related software packages(mrMLM.GUI and QTL.gCIMapping.GUI)can be downloaded from the R and BioCode websites. | Yangjun Wen Yawen Zhang Jin Zhang Jianying Feng Yuanming Zhang | 2020 | The Crop Journal2020，8，5： | 4 |
| 4 | Entinostat,a classⅠselective histone deacetylase inhibitor,plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer:A multicenter,randomized,double-blind,placebo-controlled,phase 3 trial显示文摘Entinostat plus exemestane in hormone receptor-positive(HR+)advanced breast cancer(ABC)previously showed encouraging outcomes.This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR+ABC that relapsed/progressed after≥1 endocrine therapy.Patients were randomized(2:1)to oral exemestane 25 mg/day plus entinostat(n=235)or placebo(n=119)5 mg/week in 28-day cycles.The primary endpoint was the independent radiographic committee(IRC)-assessed progression-free survival(PFS).The median age was 52(range,28—75)years and 222(62.7%)patients were postmenopausal.CDK4/6 inhibitors and fulvestrant were previously used in 23(6.5%)and 92(26.0%)patients,respectively.The baseline characteristics were comparable between the entinostat and placebo groups.The median PFS was 6.32(95%CI,5.30—9.11)and 3.72(95%CI,1.91—5.49)months in the entinostat and placebo groups(HR,0.76;95%CI,0.58—0.98;P=0.046),respectively.Grade≥3 adverse events(AEs)occurred in 154(65.5%)patients in the entinostat group versus 23(19.3%)in the placebo group,and the most common grade≥3 treatment-related AEs were neutropenia[103(43.8%)],thrombocytopenia[20(8.5%)],and leucopenia[15(6.4%)].Entinostat plus exemestane significantly improved PFS compared with exemestane,with generally manageable toxicities in HR+ABC(ClinicalTrials.gov#NCT03538171). | Binghe Xu Qingyuan Zhang Xichun Hu Qing Li Tao Sun Wei Li Quchang Ouyang Jingfen Wang Zhongsheng Tong Min Yan Huiping Li Xiaohua Zeng Changping Shan Xian Wang Xi Yan Jian Zhang Yue Zhang Jiani Wang Liang Zhang Ying Lin Jifeng Feng Qianjun Chen Jian Huang Lu Zhang Lisong Yang Ying Tian Hongyan Shang | 2023 | Acta Pharmaceutica Sinica B2023，13，5： | 3 |
| 5 | Trifolirhizin induces autophagy-dependent apoptosis in colon cancer via AMPK/mTOR signaling显示文摘Dear Editor,Colorectal cancer(CRC)is one of the most frequent diseases with high mortality around the world.Conventional treatments of CRC remain unsatisfactory due to the increasing recurrence rate and adverse reactions including neutropenia,drug resistance,etc.Recently,autophagy has been shown to be involved in regulating cancer development and progression by regulating apoptosis through pro-apoptosis proteins including caspases,in addition to being a potential target for cancer therapeutic intervention.1 Trifolirhizin(Supplementary Fig.S1a)is a natural flavonoid glycosides isolated from Sophora flavescens as well as a bioactive constituent of Xian-Lian-Ke-Li,a commercial traditional Chinese medicine for the cancer prevention.Numerous evidence manifested that trifolirhizin inhibited proliferative activity in melanoma B16 cell,lung cancer H23 cell,human ovarian A2780 cell,and human gastric cancer cell MKN45.2 However,its pharmacological effect and mechanism on CRC remain elusive.Herein,we evaluated the effect of trifolirhizin on autophagy and apoptosis on CRC as well as its related mechanisms,in order to provide evidence to develop a potential agent with less adverse effect in treating CRC. | Dongdong Sun Weiwei Tao Feng Zhang Weixing Shen Jiani Tan Liu Li Qinghai Meng Yugen Chen Ye Yang Haibo Cheng | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 3 |
| 6 | A polypyrrole-coated acetylene black/sulfur composite cathode material for lithium–sulfur batteries显示文摘Lithium–sulfur batteries are promising next-generation energy storage devices beyond conventional lithium ion batteries. However, it suffers from rapid capacity fading and poor cyclic stability. Here we report a facile in situ sulfur deposition and chemical oxidative polymerization method for preparing acetylene black/sulfur@polypyrrole(AB/S@PPy) composite as a cathode material for lithium–sulfur batteries. It is demonstrated that PPy is covered uniformly onto the surface of the AB/S composite forming a core–shell structure. In the structure, AB in the matrix and PPy on the surface acts as a combined conductive framework to provide ions and electrons transport pathways, and to inhibit the dissolution or diffusion of polysulfide into the electrolyte. The as-designed AB/S@PPy composite exhibits excellent rate capability and cyclic stability. The initial discharge specific capacity is as high as 1179.4 m Ah/g, and remains at769.3 m Ah/g after 80 cycles at 0.2 C. Even at a high rate(0.5 C), a maximum discharge capacity of 811.1 m Ah/g is still achieved for the AB/S@PPy composite after activation, and the capacity retention is over62.5% after 200 cycles. | Wu Yang Wang Yang Jiani Feng Xiujuan Qin | 2018 | Journal of Energy Chemistry2018，27，3： | 2 |
| 7 | Biomarkers of aging显示文摘Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological status.Although a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly characterized.An immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this need.Here,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory factors.To fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant. | Aging Biomarker Consortium Hainan Bao Jiani Cao Mengting Chen Min Chen Wei Chen Xiao Chen Yanhao Chen Yu Chen Yutian Chen Zhiyang Chen Jagadish K Chhetri Yingjie Ding Junlin Feng Jun Guo Mengmeng Guo Chuting He Yujuan Jia Haiping Jiang Ying Jing Dingfeng Li Jiaming Li Jingyi Li Qinhao Liang Rui Liang Feng Liu Xiaoqian Liu Zuojun Liu Oscar Junhong Luo Jianwei Lv Jingyi Ma Kehang Mao Jiawei Nie Xinhua Qiao Xinpei Sun Xiaoqiang Tang Jianfang Wang Qiaoran Wang Siyuan Wang Xuan Wang Yaning Wang Yuhan Wang Rimo Wu Kai Xia Fu-Hui Xiao Lingyan Xu Yingying Xu Haoteng Yan Liang Yang Ruici Yang Yuanxin Yang Yilin Ying Le Zhang Weiwei Zhang Wenwan Zhang Xing Zhang Zhuo Zhang Min Zhou Rui Zhou Qingchen Zhu Zhengmao Zhu Feng Cao Zhongwei Cao Piu Chan Chang Chen Guobing Chen Hou-Zao Chen Jun Chen Weimin Ci Bi-Sen Ding Qiurong Ding Feng Gao Jing-Dong JHan Kai Huang Zhenyu Ju Qing-Peng Kong Ji Li Jian Li Xin Li Baohua Liu Feng Liu Lin Liu Qiang Liu Qiang Liu Xingguo Liu Yong Liu Xianghang Luo Shuai Ma Xinran Ma Zhiyong Mao Jing Nie Yaojin Peng Jing Qu Jie Ren Ruibao Ren Moshi Song Zhou Songyang Yi Eve Sun Yu Sun Mei Tian Shusen Wang Si Wang Xia Wang Xiaoning Wang Yan-Jiang Wang Yunfang Wang Catherine CL Wong Andy Peng Xiang Yichuan Xiao Zhengwei Xie Daichao Xu Jing Ye Rui Yue Cuntai Zhang Hongbo Zhang Liang Zhang Weiqi Zhang Yong Zhang Yun-Wu Zhang Zhuohua Zhang Tongbiao Zhao Yuzheng Zhao Dahai Zhu Weiguo Zou Gang Pei Guang-Hui Liu | 2023 | Science China(Life Sciences)2023，66，5： | 2 |
| 8 | Phenolic and enolic hydroxyl groups incurcumin: which plays the major role in scavenging radicals 显示文摘 | FENG Jianying LIU Zaixun | 2009 | Journalof Agriculture and Food Chemistry2009，57，11： | 1 |
| 9 | Comments on aPractical(t,n)Threshold Proxy Signature Scheme Based on theRSA Cryptosystem显示文摘 | Wang Guilin Feng Bao Zhou Jianying | 2004 | IEEE Transactions on Knowledge and DataEngineering2004，16，10： | 1 |
| 10 | A simple me~hod for dynami~ cally measuring the diameters of train wheels using a one-dimen- sional laser displacement transducer 显示文摘 | Yah Gao Feng Qibo Cui Jianying | 2014 | Optics and Lasers in Engineering2014，53，： | 1 |
| 11 | Spatio-temporal changes in free-air freezing level heights in Northwest China, 1960–2012显示文摘 | Xiaoyan Huang Shengjie Wang Jinsong Wang Yaohui Li Jianying Feng Kai Zhang | 2013 | Quaternary International2013，，： | 1 |
| 12 | Development of low-coherence high-power laser drivers for inertial confinement fusion显示文摘The use of low-coherence light is expected to be one of the effective ways to suppress or even eliminate the laser–plasma instabilities that arise in attempts to achieve inertial confinement fusion.In this paper,a review of low-coherence high-power laser drivers and related key techniques is first presented.Work at typical low-coherence laser facilities,including Gekko XII,PHEBUS,Pharos III,and Kanal-2 is described.The many key techniques that are used in the research and development of low-coherence laser drivers are described and analyzed,including low-coherence source generation,amplification,harmonic conversion,and beam smoothing of low-coherence light.Then,recent progress achieved by our group in research on a broadband low-coherence laser driver is presented.During the development of our low-coherence high-power laser facility,we have proposed and implemented many key techniques for working with low-coherence light,including source generation,efficient amplification and propagation,harmonic conversion,beam smoothing,and precise beam control.Based on a series of technological breakthroughs,a kilojoule low-coherence laser driver named Kunwu with a coherence time of only 300 fs has been built,and the first round of physical experiments has been completed.This high-power laser facility provides not only a demonstration and verification platform for key techniques and system integration of a low-coherence laser driver,but also a new type of experimental platform for research into,for example,high-energy-density physics and,in particular,laser–plasma interactions. | Yanqi Gao Yong Cui Lailin Ji Daxing Rao Xiaohui Zhao Fujian Li Dong Liu Wei Feng Lan Xia Jiani Liu Haitao Shi Pengyuan Du Jia Liu Xiaoli Li Tao Wang Tianxiong Zhang Chong Shan Yilin Hua Weixin Ma Xun Sun Xianfeng Chen Xiuguang Huang Jian Zhu Wenbing Pei Zhan Sui Sizu Fu | 2020 | Matter and Radiation at Extremes2020，5，6： | 1 |
| 13 | Effects of ther- mal oxidative ageing on dynamic viscosity, TG/ DTG,DTA and FTIR of SBS- and SBS/sulfur-mod- ified asphalts显示文摘 | Feng Zhang Jianying Yu Jun Han | 2011 | Construction and Building Materi- als2011，25，1： | 1 |
| 14 | Effect of organo -montmorillonite on aging properties of asphalt 显示文摘 | Yu Jianying Feng Pengcheng Zhang Henglong | 2009 | Construction and Building Materials2009，23，： | 1 |
| 15 | Development and evaluation on a RFID-based traceability system for cattle/beef quality safety in China显示文摘 | Jianying Feng Zetian Fu Zaiqiong Wang Mark Xu Xiaoshuan Zhang | 2013 | Food Control2013，，2： | 1 |
| 16 | A study on the aging kinet- ics of PPA modifiedasphalt 显示文摘 | Zhang Feng Yu Jianying | 2010 | Petroleum Science and Technology2010，28，： | 1 |
| 17 | Effect of Organo-montmorillonite on Aging Properties of Asphalt 显示文摘 | Yu Jianying Feng Pengcheng Zhang Henglong | 2009 | Construction and Building Materials2009，23，6： | 1 |
| 18 | Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy显示文摘Background:Although programmed cell death 1(PD-1)blockade plus chemotherapy can significantly prolong the progression-free survival(PFS)and overall survival(OS)in first-line settings in patients with driver-negative advanced non-small-cell lung cancer(NSCLC),the predictive biomarkers remain undetermined.Here,we investigated the predictive value of tumor immune microenvironmental marker expression to characterize the response features to PD-1 blockade plus chemotherapy.Methods:Tumor tissue samples at baseline were prospectively collected from 144 locally advanced or metastatic NSCLC patients without driver gene alterations who received camrelizumab plus chemotherapy or chemotherapy alone.Tumor immune microenvironmental markers,including PD-1 ligand(PDL1),CD8,CD68,CD4 and forkhead box P3,were assessed using multiplex immunofluorescence(mIF)assays.Kaplan-Meier curveswere used to determine treatment outcome differences according to their expression status.Mutational profiles were compared between tumors with distinct expression levels of these markers and their combinations.Results:Responders had significantly higher CD8/PD-L1(P=0.015)or CD68/PD-L1 co-expression levels(P=0.021)than non-responders in the camrelizumab plus chemotherapy group,while no difference was observed in the chemotherapy group.Patients with high CD8/PD-L1 or CD68/PD-L1 co-expression level was associated with significantly longer PFS(P=0.002,P=0.024;respectively)and OS(P=0.006,P=0.026;respectively)than those with low co-expression in camrelizumab plus chemotherapy group.When comparing survival in the camrelizumab plus chemotherapy with chemotherapy by CD8/PD-L1 co-expression stratification,significantly better PFS(P=0.003)and OS(P=0.032)were observed in high co-expression subgroups.The predictive value of CD8/PD-L1 and CD68/PD-L1 co-expression remained statistically significant for PFS and OS when adjusting clinicopathological features.Although the prevalence of TP53 or KRAS mutations was similar between patients with and without CD8/PD-L1 or CD68/PD-L1 co-expression,the positive groups had a significantly higher proportion of TP53/KRAS co-mutations than the negative groups(both 13.0%vs.0.0%,P=0.023).Notably,enriched PI3K(P=0.012)and cell cycle pathway(P=0.021)were found in the CD8/PD-L1 co-expression group.Conclusion:Tumor immune microenvironmental marker expression,especially CD8/PD-L1 or CD68/PD-L1 co-expression,was associated with the efficacy of PD-1 blockade plus chemotherapy as first-line treatment in patients with advanced NSCLC. | Fengying Wu Tao Jiang Gongyan Chen Yunchao Huang Jianying Zhou Lizhu Lin Jifeng Feng Zhehai Wang Yongqian Shu Jianhua Shi Yi Hu Qiming Wang Ying Cheng Jianhua Chen Xiaoyan Lin Yongsheng Wang Jianan Huang Jiuwei Cui Lejie Cao Yunpeng Liu Yiping Zhang Yueyin Pan Jun Zhao LiPing Wang Jianhua Chang Qun Chen Xiubao Ren Wei Zhang Yun Fan Zhiyong He Jian Fang Kangsheng Gu Xiaorong Dong Tao Zhang Wei Shi Jianjun Zou Xuejuan Bai Shengxiang Ren Caicun Zhou | 2022 | Cancer Communications2022，42，12： | 1 |
| 19 | Effect of ageing on rheological properties of storage-stable SBS/sulfur-modifi ed asphalts显示文摘 | Feng Zhang Jianying Yu Shaopeng Wu | 2010 | Journal of Hazardous Materials2010，182，13： | 1 |
| 20 | Metalens-based stereoscopic microscope显示文摘Stereoscopic microscopy is a promising technology to obtain three-dimensional microscopic images.Such microscopes are based on the parallax effect,and as such require two lenses to focus at two different points.Geometrical constraints,however,restrict their numerical apertures to about 0.2,thus limiting the system’s resolution.Higher numerical apertures(.35)can be achieved with designs using only one bulk lens,but such systems are0 times more costly than the conventional ones.Thus,there is a pressing need for alternative solutions to improve the resolution of stereoscopic systems.Here,we show that high-resolution and low-cost stereoscopic systems can be obtained using birefringent single-layer metalenses.We design and fabricate a birefringent metalens operating at 532 nm with a numerical aperture as high as 0.4.The metalens is then used to demonstrate high-resolution stereoscopic imaging of biological samples.The microscopic images are further displayed and perceived vividly in an autostereoscopic display.Our demonstration paves the way to a new strategy to achieve high-resolution and low-cost stereoscopic microscopes. | YONG LONG JIANCHAO ZHANG ZHIHAO LIU WEIBIN FENG SONGMING GUO QIAN SUN QINFEI WU XIANGYANG YU JIANYING ZHOU EMILIANO RMARTINS HAOWEN LIANG JUNTAO LI | 2022 | Photonics Research2022，10，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员